Sumitomo Pharma Oncology

Sumitomo Pharma Oncology, Inc., a U.S.-based developer of novel cancer therapeutics and a wholly owned subsidiary of Sumitomo Pharma Co., Ltd., is committed to translating new discoveries into meaningful treatments for patients with cancer. SMP Oncology boasts a robust and diverse pipeline of preclinical and late-stage assets spanning multiple areas, including oncogenic pathways, survival mechanisms, and novel protein interactions, aiming to address unmet clinical needs in oncology.